Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

NCT04402723 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate policy adjustments

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Donafenib

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd